Stanislas Pol
#111,132
Most Influential Person Now
Researcher
Stanislas Pol's AcademicInfluence.com Rankings
Stanislas Polcomputer-science Degrees
Computer Science
#4197
World Rank
#4417
Historical Rank
Machine Learning
#749
World Rank
#759
Historical Rank
Artificial Intelligence
#958
World Rank
#975
Historical Rank
Database
#1428
World Rank
#1501
Historical Rank
Download Badge
Computer Science
Stanislas Pol's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Computer Science Université Paris Cité
Similar Degrees You Can Earn
Why Is Stanislas Pol Influential?
(Suggest an Edit or Addition)Stanislas Pol's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Telaprevir for retreatment of HCV infection. (2011) (1630)
- FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest (2007) (1627)
- Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. (2009) (1096)
- Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. (2004) (863)
- Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles (2002) (680)
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (2015) (621)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? (2001) (594)
- Hepatitis C Virus Type 1b (II) Infection in France and Italy (1995) (492)
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. (2013) (449)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. (2011) (416)
- Ribavirin for chronic hepatitis E virus infection in transplant recipients. (2014) (410)
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. (2017) (403)
- Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. (2016) (388)
- Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. (2007) (357)
- Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (2014) (342)
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
- Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment (2017) (324)
- Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) (2003) (294)
- Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C (2008) (288)
- Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis (2017) (285)
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial (2015) (273)
- Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. (2014) (272)
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) (2016) (271)
- Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma (2012) (260)
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis (2015) (256)
- Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. (1998) (255)
- Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. (2017) (225)
- Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B (2018) (221)
- SAFE biopsy: A validated method for large‐scale staging of liver fibrosis in chronic hepatitis C (2009) (213)
- Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. (2005) (213)
- [Epidemiology and natural history of hepatitis B]. (2005) (211)
- Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. (1999) (204)
- Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer (2004) (203)
- Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. (2011) (197)
- Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. (2014) (196)
- [Risk factors for hepatitis C virus transmission to Health Care Workers after occupational exposure: a European case-control study]. (2005) (194)
- Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. (2013) (190)
- Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. (1993) (187)
- Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography. (2015) (183)
- Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. (2001) (180)
- Induction or expansion of T‐cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers (2004) (177)
- Brief Communication: Case Reports of Ribavirin Treatment for Chronic Hepatitis E (2010) (177)
- Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. (2009) (173)
- Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. (2018) (170)
- Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. (1998) (168)
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. (2012) (168)
- The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. (1996) (161)
- Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. (1999) (160)
- Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study (2005) (159)
- Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy (2006) (158)
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). (2015) (157)
- Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. (2012) (155)
- IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes (2012) (153)
- Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. (2006) (150)
- Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. (2016) (148)
- Liver‐related mortality in human‐immunodeficiency‐virus‐infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study) * (2007) (147)
- Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. (1997) (147)
- Specific vaccine therapy in chronic hepatitis B infection (1994) (146)
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. (2014) (141)
- Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. (2016) (140)
- Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. (1996) (138)
- Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients (2007) (136)
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study (2014) (135)
- Treatment With LedipasvirSofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection (2016) (134)
- Hepatitis C virus treatment in the real world: optimising treatment and access to therapies (2015) (133)
- Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. (1991) (131)
- Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. (2011) (131)
- Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. (1993) (129)
- HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. (2004) (129)
- The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases (2011) (128)
- High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. (2018) (127)
- Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. (1998) (127)
- Intrahepatic virus‐specific IL‐10‐producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (2006) (126)
- Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. (2017) (125)
- Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients (2007) (125)
- Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. (1998) (124)
- Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. (2011) (123)
- Severe evolution of chronic hepatitis C in renal transplantation: a case control study. (2002) (122)
- The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. (1995) (122)
- Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth (2019) (119)
- Reversibility of hepatitis C virus-related cirrhosis. (2004) (119)
- First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice (2012) (119)
- Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure (2018) (116)
- Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin (2005) (116)
- Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (2013) (113)
- Interactions between human immunodeficiency virus‐1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus (1992) (111)
- Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. (1994) (110)
- Hepatitis B virus genotypes and extrahepatic manifestations. (2005) (109)
- The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B (2009) (105)
- Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. (2006) (104)
- Direct and indirect evidence for the reversibility of cirrhosis. (2006) (104)
- Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy (2005) (103)
- Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients (1995) (103)
- Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. (2005) (102)
- Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. (2017) (100)
- Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. (2006) (100)
- Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02. (2008) (99)
- Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. (2011) (98)
- Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report (2000) (98)
- The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. (2003) (97)
- Impact of common risk factors of fibrosis progression in chronic hepatitis C (2014) (96)
- Chronic hepatitis in kidney allograft recipients (1990) (96)
- Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. (1998) (95)
- Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort) (2015) (95)
- Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. (2001) (94)
- Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN (2014) (94)
- Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? (2007) (94)
- Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study (2015) (93)
- Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors (2006) (93)
- Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. (2015) (93)
- 8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2012) (93)
- PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. (2015) (93)
- Hepatitis C viremia and anti-HCV antibodies in alcoholics. (1992) (91)
- Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. (1997) (91)
- In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA (1995) (89)
- FIB‐4: A simple, inexpensive and accurate marker of fibrosis in HCV‐infected patients (2006) (89)
- The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. (2001) (88)
- Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. (2019) (87)
- Spontaneous and iatrogenic spreading of liver‐derived cells into peripheral blood of patients with primary liver cancer (1997) (85)
- Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells (1999) (84)
- HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. (2000) (83)
- Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. (2007) (83)
- Efficacy and Safety of Adefovir Dipivoxil in Kidney Recipients, Hemodialysis Patients, and Patients with Renal Insufficiency (2005) (81)
- Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers. (2012) (80)
- A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment (1999) (80)
- Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 (2013) (79)
- Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. (2017) (79)
- Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. (2008) (77)
- Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization (1994) (77)
- Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir) (2016) (76)
- Hepatitis C virus in kidney recipients. Epidemiology and impact on renal transplantation. (1992) (75)
- Antigenic relevance of F protein in chronic hepatitis C virus infection (2004) (75)
- Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. (2018) (75)
- Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. (1990) (75)
- Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial (2013) (75)
- Epidemiological and virological analysis of couples infected with hepatitis C virus (1999) (75)
- Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels (2002) (74)
- Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment (2009) (74)
- Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. (2017) (74)
- Hepatitis C: epidemiology, diagnosis, natural history and therapy. (2012) (73)
- Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. (2001) (72)
- Bradyarrhythmias Associated with Sofosbuvir Treatment. (2015) (72)
- Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C (1997) (71)
- Immunotherapy of chronic hepatitis B by anti HBV vaccine. (1998) (71)
- Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. (2018) (69)
- Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study (2011) (69)
- The Impact of Haematopoietic Growth Factors on the Management and Efficacy of Antiviral Treatment in Patients with Hepatitis C Virus (2005) (68)
- TNF alpha antagonist therapy and safety monitoring. (2011) (68)
- Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. (2018) (67)
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib (2011) (67)
- 13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY (2011) (66)
- Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. (2008) (64)
- Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). (2014) (64)
- Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. (2015) (64)
- Histopathologic Efficacy of Ribavirin Monotherapy in Kidney Allograft Recipients with Chronic Hepatitis C (2004) (63)
- Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status (2006) (63)
- Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life (2016) (62)
- The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. (2008) (59)
- Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. (1996) (59)
- The negative impact of HBV/HCV coinfection on cirrhosis and its consequences (2017) (59)
- Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. (2016) (59)
- Gaining Greater Insight into HCV Emergence in HIV-Infected Men Who Have Sex with Men: The HEPAIG Study (2011) (58)
- Diagnostic Accuracy of the Fibrotest in Hemodialysis and Renal Transplant Patients with Chronic Hepatitis C Virus (2005) (58)
- The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study (2016) (57)
- Response to pegylated interferon alfa‐2a and ribavirin in chronic hepatitis C genotype 4 (2009) (57)
- Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus (2018) (57)
- Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients. (1996) (57)
- Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. (2013) (57)
- Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY) (2007) (57)
- Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. (1994) (56)
- Tocilizumab: therapy and safety management. (2010) (56)
- Hepatitis C virus and the kidney (2018) (56)
- Combination of ribavirin and interferon‐alfa surpasses high doses of interferon‐alfa alone in patients with genotype‐1b–related chronic hepatitis C (2000) (56)
- The impact of human immunodeficiency virus on viral hepatitis (2011) (55)
- Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. (2015) (55)
- Distinct CD4+CD8+ Double-Positive T Cells in the Blood and Liver of Patients during Chronic Hepatitis B and C (2011) (55)
- Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data (2011) (55)
- Hepatitis C virus in kidney recipients (1992) (55)
- Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients (2009) (54)
- Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. (1995) (54)
- Long‐term Efficacy of Interferon‐Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis (2019) (54)
- Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. (2002) (54)
- Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort) (2015) (53)
- Extrahepatic cancers and chronic HCV infection (2018) (53)
- Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C (2004) (53)
- Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C (2013) (52)
- Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. (2008) (51)
- Effect of pregnancy on chronic hepatitis C: a case-control study (2000) (51)
- Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN α2b plus ribavirin in HIV/HCV co-infected patients (2007) (50)
- Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa (2000) (50)
- Enterocytozoon bieneusi infection in acquired immunodeficiency syndrome-related sclerosing cholangitis. (1992) (49)
- Protease inhibitor‐based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver (2012) (49)
- Treatment of acute hepatitis C in human immunodeficiency virus–infected patients: The HEPAIG study (2010) (49)
- Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. (2010) (49)
- Therapeutic vaccination in chronic hepatitis B virus carriers (2006) (48)
- Up-Regulation of the ATP-Binding Cassette Transporter A1 Inhibits Hepatitis C Virus Infection (2014) (48)
- 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS (2012) (48)
- ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis (2017) (48)
- Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. (2005) (48)
- Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area (2020) (48)
- A new indication for liver transplantation: Nodular regenerative hyperplasia in human immunodeficiency virus–infected patients (2008) (47)
- Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. (2007) (47)
- Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients (2018) (47)
- All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection (2014) (47)
- Eradication of Hepatitis C Virus RNA after Alpha-Interferon Therapy (1994) (47)
- Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients (2015) (47)
- Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study (2018) (47)
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. (2015) (46)
- 484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (46)
- Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune‐Mediated Inflammatory Diseases (2013) (46)
- Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis (2021) (46)
- Is hepatitis C virus involved in hepatitis-associated aplastic anemia? (1990) (46)
- Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients (2012) (45)
- 58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY (2008) (45)
- Hepatitis C virus genotypes in French haemophiliacs: Kinetics and reappraisal of mixed infections (1997) (44)
- Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy (2004) (44)
- 1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL (2012) (44)
- Impact and evolution of peliosis hepatis in renal transplant recipients. (1994) (44)
- HCV infection and hemodialysis. (2002) (43)
- Late presentation of chronic viral hepatitis for medical care: a consensus definition (2017) (42)
- Management of chronic hepatitis C virus infection in HIV-infected patients. (2008) (42)
- Viral hepatitis in solid organ transplantation other than liver. (2011) (42)
- Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies (2016) (42)
- Late presentation of chronic viral hepatitis for medical care: a consensus definition (2017) (42)
- Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial (2019) (41)
- Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib (2012) (40)
- Prevalence of renal abnormalities in chronic HBV infection: The HARPE study (2015) (40)
- Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. (2016) (40)
- Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: A relevant ex vivo model of liver infection (2012) (40)
- Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. (2015) (40)
- Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020 (2021) (40)
- Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life (2006) (40)
- Discrimination of agonist and antagonist forms of CXCL10 in biological samples (2012) (40)
- Associations between consumption of dietary fibers and the risk of cardiovascular diseases, cancers, type 2 diabetes, and mortality in the prospective NutriNet-Santé cohort. (2020) (39)
- Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. (1995) (39)
- LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather* (2015) (38)
- Treatment of hepatitis C: the use of the new pangenotypic direct‐acting antivirals in “special populations” (2018) (38)
- Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. (2000) (38)
- HCV and the kidney (2016) (38)
- 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2013) (38)
- Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. (1996) (38)
- Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients. (1994) (37)
- Immunological and Antiviral Responses After Therapeutic DNA Immunization in Chronic Hepatitis B Patients Efficiently Treated by Analogues. (2014) (37)
- Reversibility of Cirrhosis in HIV/HBV Coinfection (2006) (37)
- 1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (2007) (37)
- Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. (2020) (36)
- 5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN (2011) (36)
- Influence of liver biopsy on abstinence in alcohol-dependent patients. (2008) (35)
- Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study. (2018) (35)
- [HIV and hepatitis C virus coinfection]. (2008) (35)
- Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. (2014) (35)
- The Role of Adherence in Virological Suppression in Patients Receiving Anti-HBV Analogues (2012) (34)
- Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results (2013) (34)
- Changes to the Natural Killer Cell Repertoire after Therapeutic Hepatitis B DNA Vaccination (2010) (33)
- Grazoprevir/elbasvir combination therapy for HCV infection (2017) (32)
- Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men (2008) (32)
- LP02 : C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease (2015) (32)
- 1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY (2013) (32)
- 66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R (2011) (32)
- Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers (2020) (32)
- 1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS (2013) (32)
- Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV–hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study (2009) (32)
- T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study (2012) (31)
- Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy (2002) (31)
- Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (2013) (31)
- How to optimize HCV therapy in genotype 1 patients with cirrhosis (2013) (31)
- Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study (2016) (31)
- Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254]. (2008) (31)
- Treatment of chronic hepatitis C in special groups. (1999) (31)
- O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION (2014) (31)
- Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis (2004) (30)
- Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication (2018) (30)
- Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers. (2011) (30)
- Micro‐elimination of hepatitis C virus (2020) (30)
- 1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES (2012) (30)
- LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather (2015) (30)
- Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment. (2004) (30)
- Intravenous ketamine and progressive cholangiopathy in COVID-19 patients (2021) (29)
- 50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS (2012) (29)
- Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? (2000) (28)
- Liver diseases and hepatic complications in renal transplant patients. (1988) (28)
- Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. (2008) (28)
- Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx‐derived epitope (2007) (28)
- A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. (1999) (28)
- Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV–Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study – ANRS HC02 (2008) (28)
- Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. (2012) (28)
- Chronic liver disease: systemic and splanchnic venous flow mapping with optimized cine phase-contrast MR imaging validated in a phantom model and prospectively evaluated in patients. (2011) (27)
- Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. (2008) (27)
- Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin (2009) (27)
- Lack of evidence for a role of HCV in hepatitis‐associated aplastic anaemia (1993) (27)
- Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. (2014) (27)
- 1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS (2011) (27)
- Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging (2016) (27)
- Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase. (1995) (27)
- 1207 TRIPLE THERAPY WITH DACLATASVIR (DCV; BMS-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL (2012) (26)
- Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. (2015) (26)
- Nonalcoholic Fatty Liver Disease and HIV Infection (2012) (26)
- Regulation of cytosolic aspartate aminotransferase mRNAs in the Fao rat hepatoma cell line by dexamethasone, insulin and cyclic AMP. (1989) (26)
- Cost‐effectiveness and budget impact of interferon‐free direct‐acting antiviral‐based regimens for hepatitis C treatment: the French case (2016) (26)
- Impact of medical recommendations on alcohol consumption in HCV positive patients. (2001) (25)
- Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. (2017) (25)
- Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype (2008) (25)
- Monoclonal anti‐HBs antibodies radioimmunoassay and serum HBV‐DNA hybridization as diagnostic tools of HBV infection: relative prevalence among HBsAgnegative alcoholics, patients with chronic hepatitis or hepatocellular carcinomas and blood donors (1987) (25)
- 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION (2011) (25)
- Treatment of hepatitis C virus genotype 3‐infection (2014) (25)
- Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus‐coinfected patients treated with interferon plus ribavirin (2007) (25)
- [Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication]. (1993) (25)
- T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study (2012) (25)
- Hepatitis and solid organ transplantation. (2000) (24)
- Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal (2014) (24)
- Why actively promote vaccination in patients with cirrhosis? (2009) (24)
- Hepatic activity and mRNA expression of aspartate aminotransferase isoenzymes in alcoholic and nonalcoholic liver disease (1991) (24)
- Secondary immune response to hepatitis B virus vaccine in alcoholics. (1993) (23)
- IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? (2012) (23)
- Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed (2015) (23)
- Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen (2016) (23)
- Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. (2013) (23)
- MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure (2017) (23)
- Influence of human immunodeficiency virus infection on hepatitis δ virus superinfection in chronic HBsAg carriers (1994) (23)
- Diagnostic accuracy of des‐gamma‐carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer (2017) (22)
- Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon‐based therapy: FUNDAMENTAL, a Phase II trial (2015) (22)
- Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a (2008) (22)
- Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. (2007) (22)
- 1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV (2010) (22)
- Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens (2017) (22)
- 954 BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAIN (2009) (22)
- Management of HBV in immunocompromised patients (2013) (22)
- High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART? (2007) (22)
- Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. (2007) (22)
- Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease (2021) (22)
- O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS (2014) (21)
- Vaccination of chronic hepatitis B virus carriers with preS2/S envelope protein is not associated with the emergence of envelope escape mutants. (2001) (21)
- Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis (2011) (21)
- Severe weight loss in HIV / HCV‐coinfected patients treated with interferon plus ribavirin: incidence and risk factors (2008) (21)
- Dilated Bile Duct in Patients Receiving Narcotic Substitution: An Early Report (2000) (21)
- The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study (2016) (21)
- Hepatitis E Virus Infection in Sheltered Homeless Persons, France (2012) (20)
- Mycophenolate sodium-induced hepatotoxicity: first report. (2006) (20)
- Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial (2003) (20)
- Transmission of Hepatitis E Virus by Plasma Exchange: A Case Report (2016) (20)
- T‐cell responses to hepatitis B splice‐generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP‐FIBRO (2012) (20)
- SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy (2017) (20)
- Ledipasvir/Sofosbuvir for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 Hcv Infection (2016) (20)
- Subanalyses of the Telaprevir Lead-in ARM in the Realize Study: Response at Week 4 is Not a Substitute for Prior Null Response Categorization (2011) (20)
- Interferon γ receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection (2010) (20)
- Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? (2015) (20)
- The remarkable history of the hepatitis C virus (2019) (19)
- Veno-occlusive disease of the liver in renal transplant patients. (2003) (19)
- Thymosin alpha‐1 with peginterferon alfa‐2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? (2012) (19)
- High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis (2017) (19)
- Absence of hepatitis delta virus infection in chronic hemodialysis and kidney transplant patients in france. (1992) (19)
- Nucleotide sequence and tissue distribution of the human mitochondrial aspartate aminotransferase mRNA. (1988) (19)
- 1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2011) (19)
- Treatment of HBV-related cirrhosis (2009) (19)
- Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes. (2004) (18)
- Co-infection par le virus de l’immunodéficience humaine et le virus de l’hépatite C (2008) (18)
- Hepatitis C virus infection in hemodialysis patients. (2013) (18)
- Production of hepatitis B defective particles is dependent on liver status. (2012) (17)
- MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure (2017) (17)
- Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. (2011) (17)
- Hepatitis delta virus infection in French male HBsAg‐positive homosexuals (1989) (17)
- Clinical impact of drug addiction in alcoholics. (1995) (17)
- Results From the Phase 2 PEARL-I Study: Interferon-Free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection: 438 (2014) (17)
- Improving anti-hepatitis C virus therapy (2006) (17)
- Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study (2015) (17)
- In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas (2016) (17)
- Serum hepatitis C virus RNA and hepatitis B virus DNA in non-A, non-B post-transfusional and sporadic chronic hepatitis. (1992) (17)
- Histoire naturelle de l’infection par le virus de l’hépatite B (2006) (17)
- Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. (2003) (16)
- New treatments for chronic hepatitis C virus infection. (2011) (16)
- Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash (2012) (16)
- Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. (2020) (16)
- Evidence of non-A, non-B, non-C infection in chronic hepatitis by polymerase chain reaction testing for hepatitis B and C viruses. (1995) (16)
- A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. (2008) (16)
- Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. (2018) (16)
- 1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS (2012) (16)
- Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. (2020) (15)
- An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines. (2016) (15)
- Hepatic profile analyses of tipranavir in Phase II and III clinical trials (2009) (15)
- Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. (2014) (15)
- Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. (2008) (15)
- 1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2012) (15)
- 1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL (2010) (15)
- Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. (2011) (15)
- Long-term outcome of hepatitis C infection after liver transplantation. (1996) (15)
- Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients? (2009) (15)
- 49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188) (2013) (15)
- Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline (2019) (14)
- Comprehensive review of telbivudine in pregnant women with chronic hepatitis B. (2016) (14)
- Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin (2006) (14)
- Non‐virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort (2019) (14)
- Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage (2019) (14)
- Effects of interleukin-2 on hepatitis B vaccination in uraemic patients (1994) (14)
- A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus‐coinfected patients (2016) (13)
- Serum hepatitis C virus (HCV) RNA: a reliable tool for evaluating HCV‐ related liver disease in anti‐HCV‐positive blood donors with persistently normal alanine aminotransferase values (1995) (13)
- Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus. (2005) (13)
- Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialyis patients (1996) (13)
- Properties of human liver cytosolic aspartate aminotransferase mRNAs generated by alternative polyadenylation site selection. (1990) (13)
- Transmission of Hepatitis E Virus With Plasma Exchange in Kidney Transplant Recipients: A Retrospective Cohort Study (2018) (13)
- Chronic hepatitis C of drug users: Influence of HIV infection (1995) (13)
- Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up (2015) (13)
- T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study (2012) (13)
- Acute hepatitis A virus infection without IgM antibodies to hepatitis A virus. (2011) (13)
- Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009. (2010) (12)
- SPECIAL ARTICLE ESBRA 1997 AWARD LECTURE RELATIONSHIP BETWEEN EXCESSIVE ALCOHOL DRINKING AND VIRAL INFECTIONS (1998) (12)
- Triggering of acute alcoholic hepatitis by α-interferon therapy (1999) (12)
- Triggering of acute alcoholic hepatitis by α-interferon therapy (1999) (12)
- Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes. (2019) (12)
- Vaccination against Hepatitis A Virus in French Hemophilic Children (1995) (12)
- Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. (2019) (12)
- Evidence of a large international HCV transmission network in HIV-positive men who have sex with men (MSM) (2009) (12)
- Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. (1995) (12)
- Dexamethasone for alcohol withdrawal. (1991) (12)
- Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study) (2018) (12)
- MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH). (2019) (11)
- Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort) (2020) (11)
- BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease (2016) (11)
- Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? (2015) (11)
- Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. (2014) (11)
- Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: a retrospective longitudinal study (2018) (11)
- Prise en charge du risque de réactivation du virus de l’hépatite B chez les patients traités par immunosuppresseurs et immunomodulateurs en médecine interne : données de l’enquête REACTI-B et proposition d’un algorithme de prise en charge (2011) (11)
- Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine (2018) (11)
- Hepatocellular carcinoma in alcoholics. (1995) (11)
- Oral antiviral therapies for chronic hepatitis C infection (2013) (11)
- Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. (2015) (11)
- Similar 5‐year HCC occurrence in Tenofovir‐ and Entecavir‐treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort (2021) (11)
- Treatment of hepatitis C: perspectives. (2014) (11)
- Management of hepatitis C virus infection in heavy drinkers. (2013) (11)
- Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. (1998) (11)
- O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY (2014) (11)
- 1254 RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS E: A CASE-SERIES (2011) (11)
- Direct acting antivirals failure: cause and retreatment options (2018) (11)
- Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study (2019) (10)
- Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy. (2009) (10)
- An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms (2017) (10)
- 594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies (2012) (10)
- Hepatitis B virus infection and pregnancy. (2011) (10)
- 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016) (2013) (10)
- [Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences]. (2001) (10)
- Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection (2012) (10)
- P0747 : Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the Uk and Germany (2015) (10)
- Factors participating in severe HCV-related liver disease in HIV/HCV co-infection (2002) (10)
- [Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications]. (2002) (10)
- An Epidemiological and Clinical Study of Transaminase Levels and Hepatitis B Antibodies in 1,100 Blood Donors (1989) (10)
- Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysis (2017) (10)
- NNRTI‐related or ‐unrelated hepatotoxicity? (2002) (10)
- Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals. (2019) (9)
- O55 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR OF HCV GENOTYPE-1 INFECTED PATIENTS WHO FAILED PRIOR THERAPY WITH PEGINTERFERON + RIBAVIRIN PLUS 1 OR 2 ADDITIONAL DIRECT-ACTING ANTIVIRAL AGENTS (2014) (9)
- [Natural history of hepatitis B infection]. (2006) (9)
- The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C (2019) (9)
- Hepatitis Delta Virus: Epidemiology, Natural Course and Treatment (2016) (9)
- P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER (2015) (9)
- Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis (2020) (9)
- Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment (2011) (9)
- O018 : 2D-shear wave elastography is equivalent or superior to transient elastography for liver fibrosis assessment: Results from an individual patient data based meta-analysis (2015) (9)
- Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis (2021) (9)
- Immune therapy of hepatitis B virus chronic infection (2000) (9)
- Treatment of hepatitis C virus infection in dialysis patients. (2000) (9)
- LACK OF ASSOCIATION BETWEEN HCV INFECTION AND HIV‐RELATED LYMPHOMA (1999) (9)
- Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacterium tuberculosis Infection (2020) (9)
- Side effects of interferon-alpha in treating hepatitis C virus infection. (2001) (9)
- Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin‐28B rs12979860 Haplotype (2011) (9)
- Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. (2014) (9)
- New trends in hepatitis C management. (2010) (9)
- Herpesvirus infection of the respiratory tract in patients with alcoholic hepatitis. (1992) (8)
- N-acetylcysteine for paracetamol poisoning: effect on prothrombin (2002) (8)
- Hépavir, première étude observationnelle d'une cohorte de malades traités par interféron alpha-2a en monothérapie (2008) (8)
- Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency Virus (2016) (8)
- High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis (2017) (8)
- Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients. (2008) (8)
- ESBRA 1997 Award lecture: relationship between excessive alcohol drinking and viral infections. (1998) (8)
- Virus de l’hépatite C - 25 ans, la fin de l’histoire ? (2013) (8)
- Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment rationale and clinical trials (2013) (8)
- Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis (2021) (8)
- Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. (2021) (8)
- Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study. (2021) (8)
- Mycobacterium avium complex disseminated infection in a kidney transplant recipient (2016) (7)
- Impact of co-infection by hepatitis B virus and hepatitis C virus in renal transplantation. (1998) (7)
- L’hépatite B occulte (2008) (7)
- 1203 Treatment of interferon-naive patients with HCV genotype 5 with interferon (or PEG-interferon) plus ribavirin results in a very high sustained virological response (2003) (7)
- HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort (2017) (7)
- Optimizing Treatment Outcomes in Chronic Hepatitis C: Management of Non-Response (2006) (7)
- [Late presentation of Wilson's disease as cirrhosis complicating hepatocellular carcinoma]. (2003) (7)
- P0813 : All oral therapy (Sofosbuvir–Ribavirin) combination in severe HCV-mixed cryoglobulinemia vasculitis, the vascuvaldic study (2015) (7)
- Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance (2021) (7)
- Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance (2021) (7)
- Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study. (2007) (7)
- All-oral Dual Therapy with Daclatasvir and Asunaprevir in Patients with HCV Genotype 1B Infection (2014) (7)
- Efficacité d'une immunothérapie par vaccination contre le virus de l'hépatite B sur la multiplication virale B (1993) (7)
- P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL (2014) (7)
- Use of first‐generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1 (2014) (7)
- Effectiveness and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C in haemodialysis patients. (1996) (7)
- Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients (2018) (7)
- Hepatitis G virus infection in hepatitis C virus‐positive patients co‐infected or not with hepatitis B virus and/or human immunodeficiency virus (1998) (7)
- [Primary non-Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases]. (1996) (7)
- O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188) (2014) (7)
- Reversibility of hepatitis C virus-related (HCV) cirrhosis (2000) (7)
- OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results (2011) (7)
- L'hépatite B demeure un problème de santé publique en France (2010) (7)
- Ketamine-induced cholangiopathy in ARDS patients (2021) (7)
- Significance of repeatedly normal aminotransferase activities in hepatitis C virus‐infected patients (1998) (7)
- Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy". (2016) (7)
- High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients (2010) (6)
- HIV‐associated obliterative portopathy (HIV‐OP) underlies cryptogenic liver disease in HIV‐seropositive patients (2010) (6)
- Immunotherapy of chronic hepatitis B by anti HBV vaccine. (1995) (6)
- Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder‐relapser hepatitis C patients: a prospective multicentre randomized controlled study (2003) (6)
- Acute cholestatic hepatitis revealing Mycoplasma pneumoniae infection without lung involvement in an adult patient. (2009) (6)
- Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. (2017) (6)
- Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II) (2019) (6)
- Aspartate aminotransferase to platelet ratio index (APRI) score is inappropriate for assessment of liver fibrosis in HIV‐infected patients with hazardous drinking (2009) (6)
- Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors‐based therapy (2015) (6)
- Révélation tardive d'une maladie de Wilson sous la forme d'une cirrhose compliquée d'un carcinome hépatocellulaire (2003) (6)
- Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. (2008) (6)
- Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study (2015) (6)
- Histological and virological evolution of long term response after ribavirin and interferon-α combination (2000) (6)
- Evidence of a large, international network of international hepatitis C virus transmission in HIV-positive men who have sex with men (2014) (6)
- Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts (2021) (6)
- Foie, voies biliaires et infection par le virus de l'immunodéficience humaine. 1re partie : Foie, VIH et virus des hépatites B, C et D (1996) (6)
- Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study (2015) (6)
- Daclatasvir/peginterferon lambda‐1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa‐2a/ribavirin (2016) (6)
- P0713 : The impact of ledipasvir (LDV)/sofosbuvir (SOF) combination on health-related quality of life (HRQL) and patient-reported outcomes (PROS) in cirrhotic patients with chronic hepatitis C (CH-C): The sirius study (2015) (6)
- Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis. (2007) (6)
- Persistently normal alanine aminotransferase levels in HIV/HCV‐coinfected patients: the role of steatosis (2009) (6)
- LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI? (2021) (6)
- Traitement de l’hépatite chronique B : observance et tolérance (2010) (6)
- New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort) (2016) (6)
- Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing (2019) (6)
- Human immunodeficiency virus–associated obliterative portopathy underlies unexplained aminotransferase elevations under antiretrovirals (2009) (6)
- 405 SUPERSONIC SHEAR IMAGING IS A NEW POTENT MORPHOLOGICAL NON-INVASIVE TECHNIQUE TO ASSESS OF LIVER FIBROSIS. PART II: COMPARISON WITH FIBROSCAN (2010) (5)
- Predictive value of FIB‐4 versus fibrotest, APRI, FIBROINDEX and FORNS to noninvasively estimate fibrosis in hepatitis C (2008) (5)
- Dermatological side‐effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir (2016) (5)
- KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. (2022) (5)
- The remarkable history of the hepatitis C virus (2019) (5)
- Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. (2022) (5)
- Triggering of acute alcoholic hepatitis by alpha-interferon therapy. (1999) (5)
- Treatment of hepatitis C virus infection. (2020) (5)
- Iconography : Prise en charge des patients co-infectés VIH-VHC (2007) (5)
- 1167 PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE REALIZE STUDY (2012) (5)
- Can we differentiate HIV-associated obliterative portopathy from liver cirrhosis using MRI? (2019) (5)
- Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study (2020) (5)
- Hépatite C : transmission nosocomiale, état de santé et devenir des personnes atteintes (2003) (5)
- Effectiveness of adenine arabinoside 5'-monophosphate in kidney transplant recipients with chronic active hepatitis B. (1994) (5)
- Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs (2021) (5)
- H63D HFE gene mutation is a positive predictive factor to response to antiviral therapy in chronic hepatitis C (2000) (5)
- Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy (2003) (5)
- Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (5)
- Current management and recommendations on hepatitis B therapy in HIV-coinfected patients (2013) (5)
- 406 SUPERSONIC SHEAR IMAGING IS A NEW POTENT MORPHOLOGICAL NON-INVASIVE TECHNIQUE TO ASSESS LIVER FIBROSIS. PART I: TECHNICAL FEASABILITY (2010) (5)
- Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma (2021) (5)
- Interactions entre les virus de l’immunodéficience humaine et de l’hépatite C (1998) (5)
- Hépatite chronique B : situations rares : dialyse, transplantation rénale et traitements pré-emptifs en situation d’immunosuppression (2008) (5)
- Hepatitis: HBV vaccine—the first vaccine to prevent cancer (2015) (5)
- Significance of repeatedly normal aminotransferase activities in HCV-infected patients. (1999) (5)
- [FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients]. (2019) (5)
- Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfected patients (2008) (5)
- The core-specific precursor T cell response is directed to the N-terminal and central parts of the protein and positively correlates to the viral load in chronically HCV-infected patients. (2005) (5)
- Differential levels of IFNα subtypes in autoimmunity and viral infection (2021) (5)
- Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition? (2002) (5)
- Telaprevir-Based Regimen in Genotype 1 Hepatitis C Virus-Infected Patients With Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results (2011) (4)
- Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin (2009) (4)
- Histopathological Efficacy of Ribavirin Monotherapy in Hepatitis C Virus Positive Renal Transplant Patients (2005) (4)
- Traitements personnalisés du virus de l’hépatite C (2012) (4)
- [728] NODULAR REGENERATIVE HYPERPLASIA IN CHRONIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION IS LINKED TO PROTEIN S DEFICIENCY (2007) (4)
- 68 ANTIVIRAL EFFICACY OF THE NS3 PROTEASE INHIBITOR, GS-9451, NON-NUCLEOSIDE NS5b INHIBITOR, TEGOBUVIR, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS (2013) (4)
- Histological features and HLA class II alleles in HCV chronically infected patients with persistently normal alanine aminotransferase levels (2002) (4)
- P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage (2015) (4)
- "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen. (2017) (4)
- Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. (2016) (4)
- Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study) (2017) (4)
- [Treatment of chronic hepatitis B: adherence and safety]. (2010) (4)
- Severe transaminitis after interferon–ribavirin therapy in HIV/HCV‐coinfected patients: influence of a sustained HCV response (2012) (4)
- Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS). (2021) (4)
- Prise en charge de lhpatite C en 2008 (2008) (4)
- Hepatitis B Virus Genotypic Resistance to Lamivudine (1999) (4)
- Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort (2020) (4)
- Le traitement de l'hépatite B : stratégies actuelles (2007) (4)
- Effects of interleukin-2 on hepatitis B vaccination in uraemic patients. (1994) (4)
- Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study (2006) (4)
- Response to Schiano et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. (2008) (4)
- Intravenous ketamine is a risk factor for jaundice in Covid-19 patients (2021) (4)
- Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort (2019) (4)
- Management of side effects of interferon alfa and ribavirin-based treatment of chronic hepatitis C (2005) (4)
- [Hepatitis C virus: 25 years-old, the end?]. (2013) (4)
- Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). (2022) (4)
- Patients with chronic hepatitis B should be screened for hepatocellular carcinoma regardless of liver stiffness measurement (2016) (3)
- Hypertension portale chez un malade coinfecté par le virus de l’immunodéficience humaine et le virus de l’hépatite C (2007) (3)
- Épidémiologie et histoire naturelle de l’infection par le virus de l’hépatite B (2008) (3)
- Efficacy of adenine arabinoside 5'-monophosphate in kidney recipients with chronic active hepatitis B: a pilot study. (1993) (3)
- Pathological evolution of hepatitis C virus-"Healthy carriers". (2008) (3)
- Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). (2021) (3)
- Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection Genotype 1 and 6 and Chronic Kidney Disease: An Integrated Analysis (2017) (3)
- High risk of mitochondriopathy in HIV/HCV co-infected patients under concomitant DDI/D4T and interferon (standard or pegylated IFN) /ribavirin treatments (2003) (3)
- P.418 Prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) infection among HIV infected persons (France, 2004) (2006) (3)
- Is elimination of HCV realistic by 2030: France (2021) (3)
- [A puzzling case of portal hypertension in a patient with human immunodeficiency and hepatitis C virus co-infection]. (2007) (3)
- 246 ASSESSMENT OF PAROXETINE IN THE PREVENTION OF DEPRESSION IN PATIENTS WITH CHRONIC HEPATITIS C TREATED BY PEG-INTERFERON-RIBAVIRIN.: A DOUBLE-BLINDED, RANDOMIZED STUDY. ANRS HC18 PAROPEG (2010) (3)
- Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors (2018) (3)
- Targeting angiogenesis in chronic liver diseases with portal hypertension: anti–placenta growth factor inhibitor or multikinase inhibitor sorafenib? (2011) (3)
- External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV (2021) (3)
- Nouveaux traitements de l’hépatite C chronique (2012) (3)
- Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients (2011) (3)
- Virus de l’hépatite B et grossesse (2009) (3)
- Characteristics and treatment of hepatitis C virus infection in HIV-coinfected subjects. (1998) (3)
- Major models of HCV infection (2013) (3)
- 374 THE FIB-4 INDEX IS ACCURATE TO ASSESS LIVER FIBROSIS BEFORE AND DURING TREATMENT IN CHRONIC HEPATITIS B (2009) (3)
- Hépatite C en milieu psychiatrique : un réservoir oublié ? (2020) (3)
- Efficacy and safety of interferon and ribavirin therapy in HIV-HCV coinfected patients (2000) (3)
- [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health]. (2019) (3)
- 1367 RELAPSE AFTER ANALOGUES TREATMENT DISCONTINUATION IS NOT PREVENTED BY DNA VACCINATION IN CHRONIC HEPATITIS B (ANRS HB 02 VAC-ADN) (2011) (3)
- 1401 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES VARIANTS ASSOCIATED WITH LIVER FIBROSIS PROGRESSION IN HCV-INFECTED PATIENTS (2012) (3)
- Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER) (2017) (3)
- Modelling Liver Molecular Fibrogenesis In Human Liver Slices Culture. (2019) (3)
- Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort) (2016) (3)
- Prise en charge de l’infection par les virus des hépatites B ou C chez l’insuffisant rénal chronique☆ (2012) (3)
- Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort (2016) (3)
- P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir) (2015) (3)
- P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather (2015) (3)
- [Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS]. (1996) (3)
- Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. (2020) (3)
- [Management of C virus infection in patients coinfected with HIV treated with antiretroviral agents]. (2001) (3)
- [Occurrence of increased alpha-fetoprotein in non-neoplastic hepatopathies of alcoholic or non-alcoholic origin]. (1986) (3)
- Évaluation pronostique de la maladie alcoolique du foie : comment et pourquoi ? (2014) (3)
- BRIP 1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV-or HBV-related liver disease (2019) (3)
- PIN151 PATIENTS TREATED FOR HEPATITIS C: AN OBSERVATIONAL STUDY WITH THE FRENCH ADMINISTRATIVE HEALTH CARE DATABASE (SNDS) (2019) (3)
- Rapid progression of antiviral treatments of chronic hepatitis C virus infection. (2013) (3)
- Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naīve participants (2018) (3)
- 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results (2014) (3)
- Immunotherapy through vaccination inhibits hepatitis B virus multiplication (1993) (3)
- Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection (2016) (3)
- Vaccination prophylactique contre l'hépatite B : actualité et avenir (1999) (3)
- [Prophylactic vaccination against hepatitis B: present and future]. (1999) (2)
- Prévalence des anomalies rénales dans l’hépatite B chronique : résultats de l’étude HARPE (2012) (2)
- Facteurs de risque de transmission accidentelle du VHC au personnel soignant au décours d'un accident exposant au sang: une étude cas-témoins européenne (2006) (2)
- Foie et vieillissement, aspects cliniques. (2003) (2)
- Foie et antirétroviraux : hépatotoxicité, stéatose et monitoring en cas d'hépatopathie (2007) (2)
- La place de l'échographie de contraste dans la détection du carcinome hépatocellulaire (2004) (2)
- Un observatoire français du traitement des hépatites C chez les usagers de drogue : réponse au commentaire (2009) (2)
- Hépatite alcoolique aiguë (2012) (2)
- Interférons : des mécanismes d’action aux applications cliniques en hépatologie (1998) (2)
- Vaccin contre le virus de l’hépatite B et neuropathie démyélinisante : polémique et désinformation (2009) (2)
- Human Liver Fibrogenesis: The Proof of Concept of HCV-, Ethanol- or Palmitate-Induced Liver Fibrosis in the Ex Vivo Model of Human Liver Slices Culture (2016) (2)
- Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines (2018) (2)
- Effectiveness of direct‐acting antivirals for chronic hepatitis C treatment in migrant and non‐migrant populations in France (2021) (2)
- 885 IMMEDIATE vs. DELAYED TREATMENT IN GENOTYPE 4-HCV INFECTED PATIENTS IN A LIMITED RESOURCES COUNTRY: A COST-EFFECTIVENESS ANALYSIS IN EGYPT (ANRS 12215) (2013) (2)
- 1362 THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION (2011) (2)
- [Viral hepatitis in hemodialysis and renal transplantation patients]. (1994) (2)
- [Prevention and treatment of viral hepatitis in renal insufficiency conditions]. (2001) (2)
- O233: Chronic hepatitis E in immunocompromised patients (2013) (2)
- [Prognosis assessment of alcoholic liver disease: how and why?]. (2014) (2)
- Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response. (2019) (2)
- [Elimination of hepatitis C virus infection]. (2019) (2)
- Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study (2017) (2)
- HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection (2016) (2)
- [Clinical forms and prognosis of hepatitis C]. (2000) (2)
- [Gamma-glutamyltransferase, marker of abstinence on the alcoholic cirrhotic patient?]. (1985) (2)
- [Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm]. (2012) (2)
- La co-infection par les virus de l'hépatite C et de l'immunodéficience humaine (2001) (2)
- [ANRS HC 02 RIBAVIC: impact of steatosis in HIV-HCV co-infection]. (2009) (2)
- [Management of chronic hepatitis C in 2008]. (2008) (2)
- [Treatment of hepatitis C: current status and perspectives]. (2014) (2)
- 1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV (2011) (2)
- PO-066 : A Long-Term, Observational, Follow-Up Study of Patients Treated in Phase 2 and 3 Clinical Studies with Daclatasvir- Based Regimens: Efficacy and Safety Outcomes (2017) (2)
- Mortality associated with the treatment of HCV with direct-acting antivirals (2017) (2)
- HCV, ribavirin, and anemia: a new dawn. (2013) (2)
- Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with severity of liver disease (1998) (2)
- [Murderous impulses in two patients with chronic hepatitis C treated with interferon alpha]. (1998) (2)
- [Individualized treatment of hepatitis C virus infection]. (2012) (2)
- 790 INSULIN RESISTANCE IS A SPECIFIC FEATURE OF HEPATIC FIBROSIS AND STEATOSIS IN HCV MONOINFECTED PATIENTS BUT NOT IN HIV-HCV COINFECTED PATIENTS: A CASE-CONTROL STUDY (2008) (2)
- HCV infection in alcoholics (1993) (2)
- P.230 Serum alpha-fetoprotein (AFP) level predicts treatment outcome in chronic hepatitis C (ANRS 1211) (2006) (2)
- Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France (2020) (2)
- [In situ hybridization for the detection of hepatitis C virus RNA in mononuclear cells of peripheral blood from infected patients]. (1995) (2)
- Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes (2022) (2)
- An overview of serum mitochondrial aspartate aminotransferase (mAST) activity as a marker of chronic alcohol abuse. (1991) (2)
- Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes (2021) (2)
- HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management (2021) (2)
- Immune therapy of hepatitis B virus (HBV) chronic infection. European experience. (2000) (2)
- Editorial: reciprocal interaction between HCV direct‐acting anti‐virals (DAA) and hepatocellular carcinoma (HCC)—a negative impact of HCC on sustained virologic response not of DAA on HCC (2019) (2)
- Clinical validation of a rapid point of need HCV molecular test (2017) (2)
- 791 IMPACT OF ANTIVIRAL TREATMENT ON NON INVASIVE PREDICTORS OF LIVER FIBROSIS IN HIV-HCV CO-INFECTED PATIENTS: THE FIBROVIC 2 STUDY-ANRS HC02 (2008) (2)
- Shear wave dispersion for fibrosis, steatosis and activity staging (2013) (2)
- Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay (2017) (2)
- 809 IMMEDIATE OR DELAYED TREATMENT INITIATION WITH “PREVIR” CONTAINING REGIMENS IN HCV-INFECTED NAIVE GENOTYPE 1 (G1) PATIENTS WITHOUT SEVERE FIBROSIS? A COST-EFFECTIVENESS ANALYSIS (ANRS N°12188) (2013) (2)
- 775 INSULIN RESISTANCE AND RESPONSE TO THERAPY IN HIV-HCV COINFECTED PATIENTS: HOMAVIC-ANRS HC-02 STUDY (2008) (2)
- Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers (2022) (2)
- Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort) (2021) (2)
- Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection (2018) (2)
- [Hepatitis C virus and human immunodeficiency virus co-infection]. (2001) (2)
- Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis (2021) (2)
- Sequential treatment with lamivudine and interferon in patients with chronic hepatitis B non responder to interferon alone (2000) (1)
- Résistance aux analogues de nucléosides dans le traitement de l'hépatite chronique B (2003) (1)
- DPP4 inhibition reveals interleukin-33-dependent eosinophil-mediated tumor immunity in hepatocellular carcinoma (2017) (1)
- External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B (2022) (1)
- Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
- G08 : Incidence of hepatocellular carcinoma (HCC) and complications in alcoholic compensated cirrhosis. Preliminary results of a multicenter prospective French and belgian cohort (INCA Cirral) (2015) (1)
- Epidemiology update for HCV and HBV in ESRD in France: Still a lot to do (2017) (1)
- ANRS HC 02 RIBAVIC: Impact de la stéatose au cours de la co-infection VHC-VIH (2009) (1)
- Aptitude médicale du personnel soignant présentant une infection chronique par le virus de l’hépatite B (2012) (1)
- Genotype 4 HCV infection is associated with a poor response to interferon alpha: Results from a matched study (2000) (1)
- Étude transversale des atteintes rénales dans la cohorte de patients infectés par la VHC (HepatherPrévalence) de l’insuffisance rénale chronique (IRC) et facteurs associés chez les patients mono-infectés par le virus de l’hépatite C (VHC) dans la cohorte ANR (2016) (1)
- Traitements de l'infection par le virus de l'hépatite C (2017) (1)
- Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
- Benefits of HCV eradication in compensated cirrhotic patients extend beyond liver-related complications: results from the ANRS CO12 CirVir prospective cohort (2015) (1)
- Persistence to Treatment of Chronic Hepatitis B Virus (Hbv) Infection: A Study Based on the French Ims Lifelink Treatment Dynamics (LTD) Database. (2014) (1)
- L'hépatologue et l'infection par le virus de l'immunodéficience humaine (VIH) : 20 ans après... (2007) (1)
- Securing wider EU commitment to the elimination of hepatitis C virus (2022) (1)
- Serum hepatitis C virus RNA and hepatitis B virus DNA in NANB post transfusional and sporadic hepatitis (1991) (1)
- Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy (2019) (1)
- Chromosomal localization of human aspartate aminotransferase genes by in situ hybridization (1989) (1)
- [Treatment of delta (type D) hepatitis]. (2005) (1)
- Hepatitis C infection in alcoholics. (1991) (1)
- Hepatitis C virus-specific cellular immune responses in individuals with no evidence of (2012) (1)
- Situation actuelle et perspectives du dépistage et du traitement curatif des hépatites B et C en France (2016) (1)
- [New developments in ultrasound imaging for chronic liver diseases: from anatomic imaging to structural and functional imaging]. (2012) (1)
- [Hepatitis B vaccine and demyelinating diseases: debate and disinformation]. (2009) (1)
- 558 Risk factors for bacterial infections in HIV/HCV-coinfected patients during interferon plus ribavirin-based therapy (2006) (1)
- Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. (2022) (1)
- Treatment options in HIV–HCV-coinfected patients (2013) (1)
- Virological and histopathological efficacy of anti-viral therapy in HCV-related cirrhosis (2002) (1)
- SAT-269-The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who don’t achieve sustained virologic response (2019) (1)
- Transplantation and viral hepatitis: major progress (2006) (1)
- A randomized controlled trial of pegylated-interferon alpha-2B + ribavirin vs interferon alpha-2B + ribavirin in HIV co-infected patients (2003) (1)
- White Paper Non-Invasive Staging of Liver Fibrosis with ShearWave TM Elastography Imaging (2012) (1)
- 2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting (2021) (1)
- Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response. (2014) (1)
- [Alcohol, steatohepatitis, insulin resistance and hepatitis C]. (2008) (1)
- Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study) (2020) (1)
- Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study (2016) (1)
- Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort) (2022) (1)
- Advances in diagnostic imaging: The value of contrast-enhanced ultrasound for liver (2006) (1)
- Le porteur « sain » de l'antigène HBs (2000) (1)
- Traitement de l’hépatite C chronique (2011) (1)
- O3 * FREE ORAL COMMUNICATIONS 3: ALCOHOL USE AND LIVER DISEASE (2013) (1)
- Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
- Co-infection par le virus de l'immunodéficience humaine (VIH) et le virus de l'hépatite C (VHC) : épidémiologie, gravité, nouveaux aspects thérapeutiques (2005) (1)
- Co-infection VIH/VHB (2002) (1)
- 0428: Cardiac arrhythmia after initiation of sofosbuvir-including regimen in patients with chronic hepatitis C virus infection (2016) (1)
- HCV-infected dialysis patients: History is changing. (2019) (1)
- [Co-infection HIV/HBV]. (2002) (1)
- What happens after hepatitis C eradication? (2012) (1)
- [Interactions between the human immunodeficiency virus and hepatitis C virus]. (1998) (1)
- 1023 ADHERENCE TO ANTI-HBV ANALOGUES IN CLINICAL PRACTICE IS ASSOCIATED WITH VIROLOGICAL EFFICACY AND DEPENDS ON THE DURATION OF TREATMENTS AND THE PHYSICIAN'S EXPERIENCE (2010) (1)
- Improving anti-HCV therapy. (2006) (1)
- Nouveautés dans l’imagerie des hépatopathies : de l’imagerie anatomique à l’imagerie structurelle et fonctionnelle en ultrasons (2012) (1)
- Traitement de l'hépatite chronique B (2008) (1)
- Profiling of routine serum parameters and AFP evolution in cirrhosis following HCVeradication for stratification of HCC risk: a trajectory clustering analysis from the ANRS CO12 CirVir cohort (2020) (1)
- Identifying residual risk of hepatocellular carcinoma following hepatitis C virus eradication in compensated cirrhosis: decision-tree and random forest models developed in the French multicenter prospective ANRS CO12 CirVir cohort (2017) (1)
- Large scale validation of the safe (sequential algorithms for fibrosis evaluation) biopsy in chronic hepatitis C (2007) (1)
- Baseline sensitivity of T cells to alpha‐IFN correlates with sustained virological response to IFN‐based triple therapy in HCV infection (2015) (1)
- [Treatment of chronic hepatitis C: interferon alpha-2b alone or in combination with ribavirin]. (1999) (1)
- [Coinfection of hepatitis C virus and human immunodeficiency virus and antiretroviral multitherapies]. (1999) (1)
- [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure]. (2015) (1)
- [509] WHICH PATIENTS WITH CHRONIC HEPATITIS B ARE TREATED AND HOW: A CROSS-SECTIONAL STUDY IN FRANCE ON 1790 PATIENTS (2007) (1)
- Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. (2019) (1)
- PGA score In diagnosis of alcoholic fibrosis (1994) (1)
- Traitements des infections par le virus de l'hépatite C (2001) (1)
- ANRS HC 02 RIBAVIC : Du protocole multicentrique à l’optimisation des pratiques quotidiennes (2009) (1)
- Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection (2012) (1)
- Impaired liver expression of the peroxysome proliferator-activated receptor (PPAR)-A modulates liver steatosis and inflammation during hepatitis C virus (HCV) infection (2002) (1)
- Épidémiologie de la stéato-hépatite non alcoolique. Étendue du problème et son impact sur la santé publique (2019) (1)
- Hépatites virales Des progrès majeurs (2011) (1)
- Effect of pregnancy on chronic hepatitis C (2001) (1)
- Letter: more studies are needed to elucidate the impact of HBV/HCV coinfection on cirrhosis and its consequences—Authors’ reply (2018) (1)
- Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort) (2016) (1)
- Tu1019 High Rates of Adherence to Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Patients With Cirrhosis: Data From the Turquoise-II Study (2015) (1)
- [Treatment of viral hepatitis in drug addicts]. (2000) (1)
- HCV in the haemodialysis population: Treat now or later? (2020) (1)
- Phase III, Multicenter Open-Label Study to Investigate the Efficacy of Elbasvir and Grazoprevir Fixed-Dose Combination for Eight Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with Non-Severe Fibrosis (2020) (1)
- Hepatitis C virus infection is associated with impaired expression and transcriptional activity of the peroxisome proliferator activated receptor alpha (2004) (1)
- Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis (2016) (1)
- [Chronic hepatitis B: unusual situations: dialysis, renal transplantation and pre-emptive therapy in immune compromised patients]. (2008) (1)
- [Hepatitis C in a psychiatric setting: A forgotten reservoir?] (2020) (1)
- OZONOTHERAPY IN THE COMPLEX TREATMENT OF PURULENT – INFLAMMATORY COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS (2010) (1)
- Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals (2022) (1)
- [New treatments of chronic hepatitis C]. (2012) (1)
- Entcrocytozoon bieneusi infection in AIDs-related cholangitis (1991) (1)
- FP267C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE (2015) (1)
- Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. (2022) (1)
- Adaptation posologique et fonction rénale chez la personne âgée en officine. Résultat de l’étude IPOP (2016) (1)
- Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered” (2021) (1)
- [Should healthy carriers of HBs antigen be followed-up?]. (1996) (1)
- Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFNa/ (2013) (1)
- Letter: tenofovir may be superior to entecavir for treatment‐naïve chronic hepatitis B patients—authors’ reply (2021) (1)
- Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients (2021) (1)
- 1177 BASELINE Phospho-Stat1 LEVEL IN PBMC IS A NON-INVASIVE BIOMARKER OF EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY IN CHRONIC HCV INFECTION – ANRS C10–08 STUDY (2013) (1)
- COL01-02: La cinétique virale précoce n’est pas prédictive de la réponse au traitement par sofosbuvir + ribavirine (12 ou 24 semaines) chez les patients infectés par un génotype 2 ou 3 (étude VALENCE) (2014) (1)
- [Assessment and reversibility of liver fibrosis in viral hepatitis]. (2011) (1)
- C030 - Entecavir chez les malades co-infectés VIH-VHB : efficacité et tolérance dans une étude de phase ii (AI463-038) (2005) (1)
- Traitement des hépatites virales dans les situations d'insuffisance rénale (2002) (1)
- [Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses]. (1996) (1)
- Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study (2017) (1)
- Natural course of HCV infection in haemodialysed patients (2000) (1)
- Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. (2005) (1)
- Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. (2021) (1)
- Traitements des hépatites virales delta (2005) (1)
- Is the sexual transmission of HCV real (1995) (1)
- Direct, indirect and total effect of HIV coinfection on the risk of non‐liver‐related cancer in hepatitis C virus‐infected patients treated by direct‐acting antivirals: a mediation analysis (2021) (1)
- Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. (2022) (1)
- Reply to Perrella et al. (2005) (0)
- IL-17A in Human Liver: Significant Source of Inflammation and Trigger of Liver Fibrosis Initiation (2022) (0)
- PGI10 MODELLING THE IMPACT OF TREATMENT WITH ENTECAVIR ON HEALTH CARE COSTS OF CHRONIC HEPATITIS B IN FRANCE (2010) (0)
- Syddansk Universitet Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography An individual patient data based meta-analysis (2017) (0)
- 954 – Chronic Hepatitis C (CHC) Patients Who Do Not Achieve Sustained Virologic Response (SVR) Experience Worsening of Their Health-Related Quality of Life (HRQL) (2019) (0)
- [Hepatitis B remains a public health problem in France]. (2010) (0)
- Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir—new clues from Europe. Authors' reply (2021) (0)
- Iconographies supplémentaires de l'article : Rein et infection chronique par le virus de l'hépatite C (2019) (0)
- Long-term histopathological impact of IFN alpha in chronic hepatitis C (2001) (0)
- Research on Psychoimmunology (2003) (0)
- Reply to: Entecavir in the treatment of chronic hepatitis B in kidney transplantation (2012) (0)
- 666 ROLE OF HEPATIC CYCLIC AMP IN THE RENAL DYSFUNCTION ASSOCIATED TO THE DEVELOPMENT OF ASCITES IN PATIENTS WITH CIRRHOSIS (2012) (0)
- Autoévaluations de l'article : Carcinome hépatocellulaire et hépatocarcinogenèse virale (2010) (0)
- Letters to the Editor: Reply (2000) (0)
- Early IFNβ secretion determines variable downstream IL-12p70 responses upon TLR4 activation in health and disease. (2020) (0)
- Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France (2017) (0)
- [The irreversibility of cirrhosis: "the jostle dogma"]. (2005) (0)
- Autoévaluations de l'article : Rein et infection chronique par le virus de l'hépatite C (2019) (0)
- 706 A DESENSITIZATION TO ALPHA-2 INTERFERON COULD ACCOUNT FOR NON-RESPONSE IN CHRONIC HEPATITIS C (2010) (0)
- P738 NO CLINICALLY RELEVANT DRUG–DRUG INTERACTIONS BETWEEN FALDAPREVIR AND PEGYLATED INTERFERON a-2a PLUS RIBAVIRIN IN HCV-INFECTED PATIENTS: PHARMACOKINETIC ANALYSES FROM TWO PHASE II STUDIES (2014) (0)
- Author response: Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients (2015) (0)
- P.138 Evaluation of a new, non-invasive marker for fibrosis (FIB-4) in a large series of patients infected by the hepatitis C virus alone (2006) (0)
- [Hepatitis virus infection: key messages]. (2018) (0)
- La veinopathie portale oblitérante, une maladie hépatique émergente chez les patients infectés par le VIH (2009) (0)
- 1117-P: High Rate of Histologically Proven NASH and Advanced Fibrosis in Outpatients with Type 2 Diabetes Screened for NAFLD (2022) (0)
- [Clinical significance of detection and quantification of hepatitis C virus RNA in hemodialysis: proposal for a rational diagnostic strategy]. (1997) (0)
- Iatrogenic spreading of liver derived cells by liver resection and needle biopsy in patients with primary liver cancer (1998) (0)
- Eurosurveillance-View Article (2008) (0)
- 405 HARPE STUDY: PREVALENCE OF RENAL ABNORMALITIES IN CHRONIC HBV INFECTION (2013) (0)
- Arbres décisionnels de l'article : Traitements de l'infection par le virus de l'hépatite C (2017) (0)
- Serum α-Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C (2007) (0)
- The IL-17a and IL-22 cytokines like triggers of human liver fibrosis (2020) (0)
- 223 Reversibility of cirrhosis is associated with a decrease of liver-related complications (2004) (0)
- Influence du système HLA de classe II (CMH II) sur la fibrose hépatique chez les patients atteints d'hépatite chronique C (1998) (0)
- Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study (2022) (0)
- HIV/HBV Coinfection (2015) (0)
- Optimal Management of HIV-HCV Coinfection (2014) (0)
- Burden of hepatocellular cancer in patients with type-2 diabetes mellitus: a 2011–2020, french, longitudinal, retrospective, national, cohort study (2022) (0)
- CA36 - Facteurs de risque de la stéatose hépatique chez les malades co-infectés VIH/VHC (2005) (0)
- Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts (2020) (0)
- THU-152-New in France: Universal access for HCV-treatment as demonstrated by a nationwide real-world cohort (2019) (0)
- ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts (2022) (0)
- 437 Induction of HBS-specific T cell responses in HBV chronic carriers by an hepatitis B virus DNA vaccine (2004) (0)
- CLINICAL FEATURES Influence of Liver Biopsy on Abstinence in Alcohol-Dependent Patients (2008) (0)
- Total or Sub-Total Correction of a Marked and Long-standing Cardiac Dysrhythmia after Sofosbuvir/Ledispavir Treatment (2017) (0)
- 654 PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS IN A PRIMARY CULTURE OF HUMAN LIVER SLICES (2010) (0)
- 948 INCREASING INCIDENCE OF AUTOIMMUNE HEPATITIS (2013) (0)
- [Treatments for hepatitis virus C infections]. (2001) (0)
- CA 10-Hyperplasie nodulaire régénérative et thrombophilie : cause d’hypertension portale non cirrhotique au cours de l’infection par le VIH (2006) (0)
- Hepavir: The first observational study of patients treated with alpha 2-a interferon for chronic hepatitis C (2008) (0)
- 1158 PEG-IFNA/RIBAVIRIN/PROTEASE INHIBITOR COMBINATION IS HIGHLY EFFECTIVE IN HCV-MIXED CRYOGLOBULINEMIA VASCULITIS (2012) (0)
- Liver fibrosis and all‐cause mortality in chronic HCV‐infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER) (2021) (0)
- Impact of Extending DAA Availability in France: A Five-Year Overview (2015-2019) of Data From French Administrative Healthcare Databases (SNDS) (2021) (0)
- What happens after hepatitis C eradication? (2012) (0)
- Co-infection par le virus de l'hépatite C et par le virus de l'immunodéficience humaine (1998) (0)
- Hepatitis delta virus infection in human immunodeficiency virus‐positive patients (1990) (0)
- The Relationship between FIB-4 Index Variations and Outcome in Patients with Chronic Hepatitis C and Cirrhosis: Comparison with Liver Stiffness Measurement (2016) (0)
- P.247 Prediction of treatment outcome in genotype 4 chronic hepatitis C patients during combined pegylated interferon alpha-2a and ribavirin therapy (ANRS 1211 trial) (2006) (0)
- [The hepatologist and human immunodeficiency virus (HIV): 20 years later...]. (2007) (0)
- 617 IDENTIFICATION OF A GENETIC POLYMORPHISM CLEARLY INVOLVED IN HCV-RELATED FIBROSIS PROGRESSION (2008) (0)
- Arbres décisionnels de l'article : Foie et virus de l'immunodéficience humaine (2017) (0)
- P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic (2015) (0)
- OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study (2011) (0)
- Hepatic activities and mRNAs expressions of aspartate aminotransferase isozymes during liver disease (1989) (0)
- Changes in the Profile and Care of HIV-HCV Seropositive Patients in TwoCross-Sectional Surveys in France (2006 and 2013) (2014) (0)
- How Manage HCV Patients on Hemodialysis? (2015) (0)
- A new 3 p 25 locus is associated with liver fibrosis progression in HIV / HCV co-infected patients (2016) (0)
- ANRS HC 02 RIBAVIC : Impact histologique (2009) (0)
- Co-infections par les virus de l'hépatite C et de l'immunodéficience humaine : Hépatites C et nouveaux virus (1999) (0)
- Informations supplémentaires de l'article : Foie et virus de l'immunodéficience humaine (2011) (0)
- Diagnostic sérologique des hépatites virales (2001) (0)
- Withdrawal of nucleos(t)ide analogues in the treatment of chronic hepatitis B: a cornelian choice. (2021) (0)
- Alcool et marqueurs biologiques (2013) (0)
- 613 THE ANTIFIBROTIC PENTOXYPHILLINE/A-TOCOPHEROL ASSOCIATION DOES NOT LIMIT LIVER FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C – ANRS HC 10 (2009) (0)
- 455 APOLIPOPROTEIN H IS STRONGLY ASSOCIATED WITH IL28B SNP GENOTYPE AND PREDICTS VIRAL CLEARANCE IN BOTH ACUTE AND CHRONIC HEPATITIS C VIRUS INFECTION (2013) (0)
- Histoire naturelle de l’infection virale B (1998) (0)
- Échographie de contraste et carcinome hépatocellulaire (2007) (0)
- Prise en charge des hépatites virales A, B, C, D et E chez les patients dialysés (2018) (0)
- Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022 (2023) (0)
- Réversibilité des cirrhoses : impact sur les complications et la mortalité (2008) (0)
- 557 Risk factors for anemia in HIV/HCV-coinfected patients during IFN-ribavirin-based therapy (2006) (0)
- Overall mortality in patients with chronic hepatitis C: major effects of social vulnerability, tobacco smoking, and history of unhealthy alcohol use (ANRS CO22 HEPATHER cohort) (2022) (0)
- Histiocytose maligne. Rémission de plus de 5 ans. (1990) (0)
- [Occult hepatitis B virus infection]. (2008) (0)
- PS-086-Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity (2019) (0)
- Virus de l’hépatite B: qui ne pas traiter? (2009) (0)
- Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors (2022) (0)
- Régression d’une lymphoprolifération CD30+ après traitement antiviral pour une hépatite E chronique (2017) (0)
- CA28 - LES COMPLICATIONS VASCULAIRES DE LA PONCTION BIOPSIE HÉPATIQUE PAR VOIE TRANSJUGULAIRE (2004) (0)
- Bénéfices histologiques associés au traitement de l'infection virale B. Impact de la virosuppression sur l'amélioration histologique (2010) (0)
- CL4-04 RIBAVIC ANRS HC02: essai thérapeutique évaluant l'efficacité et la tolérance de l'interféron (PEG-IFN α2b versus IFN α2b) en association avec la ribavirine chez les patients porteurs d'une hépatite chronique C non traitée et coinfectés par le VIH (2004) (0)
- CA40 - TRAITEMENT DES HÉPATITES AIGUËS C PAR INTERFÉRON ALFA-2A PÉGYLÉ EN ÉGYPTE (ESSAI ANRS 1213) (2005) (0)
- Poids des effets secondaires des traitements antiviraux de l'hépatite C (1999) (0)
- CA 64 - ÉVALUATION À 3 ANS DU RISQUE D'HÉPATOPATHIE TERMINALE CHEZ LES MALADES CO-INFECTÉS VIH/VHC APRÈS TRAITEMENT DE L'HÉPATITE CHRONIQUE C (2006) (0)
- Épidémiologie, gravité, nouveaux aspects thérapeutiques de la co-infection VIH-VHC (2006) (0)
- Treatment of chronic hepatitis C. (1999) (0)
- De la réversibilité des cirrhoses (2004) (0)
- Place des facteurs de croissance hématopoïétiques dans le traitement antiviral C (2010) (0)
- Iconographies supplémentaires de l'article : Hépatites virales (2007) (0)
- 2Description des patients psychiatriques traités pour le VHC par agents antiviraux directs et impact du traitement : étude réalisée à partir des données du Système national des données de santé entre 2015-2019 (2022) (0)
- L’insulinorésistance diminue la réponse virologique soutenue au traitement interféron-ribavirine, chez les patients co-infectés VIH–VHC : étude HOMAVIC-ANRS HC02 (2008) (0)
- Efficacité des traitements anti-viraux chez les malades infectés par un VHC de type 4 en France (2008) (0)
- Sofosbuvir et les inhibiteurs NS5A chez les patients co-infectés VIH/VHC (2016) (0)
- 609 BASELINE CHARACTERISTICS AND WEEK-4 RESPONSE AMONG 1546 CHC PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 AND 4: INTERIM RESULTS OF THE PROPHESYS COHORT (2009) (0)
- Foie et virus de l'immunodéficience humaine (2011) (0)
- Rein et infection chronique par le virus de l'hépatite C (2019) (0)
- CA 31 - HÉPATITE AUTOIMMUNE : L'EXISTENCE D'UNE CIRRHOSE AU MOMENT DU DIAGNOSTIC A-T-ELLE UN IMPACT PRONOSTIQUE ? (2006) (0)
- Étude de la charge virale intrahépatique du VHC par l'association de l'immunohistochimie et de la quantification de l'ARN du VHC sur des cellules microdisséquées (2008) (0)
- Bénéfices associés aux traitements antiviraux C et résultats dans la vraie vie (2015) (0)
- Efficacité d'un traitement par interféron (standard ou pégylé) associé a la ribavirine chez des malades naïfs infectés par le virus de l'hépatite C de génotype 5 (2008) (0)
- Impact du statut vitaminique D sur la fibrose hépatique chez les patients co-infectés VIH-VHC (2011) (0)
- Economies et politique de santé: l'exemple du virus de l'hépatite C. (1996) (0)
- Nouveaux traitements de l’infection chronique par le virus de l’hépatite C (2012) (0)
- P.263 Combination of interferon and ribavirin in the treatment of dialysis patients with chronic hepatitis C (2006) (0)
- Virus des hépatites (1994) (0)
- Regulation des isoenzymes de l'asparate aminotransferase au cours des hepatopathies chez l'homme (1992) (0)
- Gastrointestinal , Hepatobiliary and Pancreatic Pathology Dual Role of CCR 2 in the Constitution and the Resolution of Liver Fibrosis in Mice (2010) (0)
- HIV co-infection and risk of morbidity and mortality in HCV patients treated by DAA (2020) (0)
- Traitement de l'hépatite C chez les patients infectés par le VIH dans la «vraie vie»: modifications de la prise en charge entre 2004 et 2006 (2007) (0)
- Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? (2014) (0)
- P.193 HCV-specific immune responses in HCV-uninfected individuals (2006) (0)
- Épidémiologie, histoire naturelle et traitements de l'infection virale delta (2016) (0)
- Rash sous télaprévir: quelle prise en charge? (2012) (0)
- Le foie des personnes vivant avec le VIH (2010) (0)
- Étude du génotype, de l'histologie hépatique et du système HLA de classe II d'un groupe de 83 malades porteurs d'une hépatite C chronique A ALAT normales (2008) (0)
- CA11 - EFFICACITÉ ET TOLÉRANCE DE L'ADÉFOVIR DIPIVOXIL AU COURS DU TRAITEMENT DE L'HÉPATITE CHRONIQUE B APRÉS ÉCHAPPEMENT À LA LAMIVUDINE CHEZ DES MALADES TRANSPLANTÉS RÉNAUX ET HÉMODIALYSÉS (2004) (0)
- Impact of chronic hepatitis on kidney allograft recipients survival (1989) (0)
- Hépatologie « transversale » : l’exemple de l’infection par le virus de l’immunodéficience humaine : 20 ans après… (2008) (0)
- [HVB and HVC infections in nephrology]. (2001) (0)
- Hépatite C chronique : bénéfices hépatiques et extrahépatiques attendus après traitement antiviral (2013) (0)
- [Viral hepatitis: major progress]. (2011) (0)
- Traitement de l’infection virale B chronique. Le point de vue de l'hépatologue sur la tolérance rénale (2010) (0)
- Hépatites auto-immunes : aspects physiopathologiques, cliniques et thérapeutiques (1998) (0)
- Validation externe du fibrotest chez les co-infectés VIH-VHC (2008) (0)
- Traitement de l'hépatite C (2014) (0)
- Long lasting suppression of disease liver activity may lead to a reversibility of cirrhosis (2001) (0)
- Indications actuelles du traitement de l'hépatite C (2004) (0)
- CA19 - Réponses T spécifiques anti-VHC chez les sujets exposés non infectés (2004) (0)
- Hepatitis: HCV virologic response—new nomenclature recommendations (2012) (0)
- High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. (2023) (0)
- Corrigendum (2021) (0)
- 625 RISK FACTORS FOR HEPATOTOXICITY OF ARV IN HIV/HCV CO-INFECTED PATIENTS WITH A 6 YEARS FOLLOW-UP AFTER A COMPLETION OF A FULL COURSE ANTI-HCV TREATMENT (2009) (0)
- Iconography : Co-infection VIH/VHB (2008) (0)
- L'administration d'érythropoiétine ou de GM-CSF permet de maintenir le traitement par interféron pégylé plus ribavirine : une analyse descriptive (2008) (0)
- COL01-01: Efficacité du retraitement par sofosbuvir des patients infectés par un génotype 1 du VHC en échec d’un traitement par peginterféron + ribavirine et 1 ou 2 autres antiviraux à action directe (2014) (0)
- [Treatment of chronic viral hepatitis]. (1992) (0)
- [Should HCV patients co-infected with HIV be treated? When? How?]. (2004) (0)
- Effect of prevalence of liver fibrosis stages in the performance of non-invasive fibrosis biomarkers in chronic liver diseases (CLDs): Results of an independent, international study (2009) (0)
- Traitements actuels et futurs de l'hépatite chronique B (2003) (0)
- Iconography : Hepatitis B virus infection and pregnancy (2011) (0)
- Cloning and sequencing of human liver cytosolic and mitochondrial aspartate aminotransferase cDNAs (1989) (0)
- [Viral hepatitis. Biological hepatic anomalies in an asymptomatic patient]. (2002) (0)
- TRAITEMENT DES HEPATITES PAR L'INTERFERON ALPHA (1996) (0)
- 1205 PRELIMINARY EVALUATION OF A NEW AUTOPHAGY INHIBITOR ANTIVIRAL AGENT FOR HEPATITIS C VIRUS IN AN EX VIVO MODEL OF HUMAN LIVER SLICES CULTURE (2013) (0)
- OP0235 Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: a long-term follow-up study (2018) (0)
- ANRS HC 02 RIBAVIC : Du protocole multicentrique à l’optimisation des pratiques quotidiennes. Conclusions (2009) (0)
- De nouvelles recommandations pour le diagnostic et le suivi virologique des hépatites virales (2003) (0)
- CA 24 - UN SCORE SIMPLE ET ÉCONOMIQUE APPELÉ FIB4 PEUT SOUVENT REMPLACER D'AUTRES MÉTHODES INVASIVES OU COÛTEUSES POUR ÉVALUER LA FIBROSE HÉPATIQUE DANS L'HÉPATITE CHRONIQUE C (2006) (0)
- Efficacité du retraitement par sofosbuvir des patients infectés par un génotype 1 du VHC en échec d’un traitement par peginterféron + ribavirine et 1 ou 2 autres antiviraux à action directe (2014) (0)
- 801 A PRIMARY CULTURE ADULT HUMAN LIVER SLICES: AN EX VIVO MODEL OF HCV DE NOVO INFECTION (2011) (0)
- Iconography : Foie et vieillissement, aspects cliniques (2008) (0)
- Traitement de l’infection chronique par le virus de l’hépatite B chez les patients co-infectés ou non par le VIH : étude EPIB-2008 (2010) (0)
- Facteurs socio-comportementaux associés à la mortalité de cause hépatique et non hépatique chez les patients atteints d’hépatite C chronique (cohorte ANRS CO22 HEPATHER) (2021) (0)
- Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study (2022) (0)
- Épidémiologie, transmission et dépistage des hépatites virales (2013) (0)
- Réversibilité des cirrhoses (2008) (0)
- C09 - Résultats finaux de ribavic (ANRS Hc02) : étude contrôlée randomisée de l’interferon pégylé alfa-2b plus ribavirine vs interferon alfa-2b plus ribavirine chez les co-infectés VIH/VHC (2004) (0)
- Traitement de l’infection virale B et prévention du carcinome hépatocellulaire (2015) (0)
- Ténofovir disoproxil sous forme de fumarate (TDF) pour le traitement de l’hépatite B chronique chez des patients AgHBe-négatif : résultats à 72 semaines et données à 24 semaines après remplacement d’adéfovir dipivoxil par TDF (étude 102) (2008) (0)
- 16 Traitement de la cirrhose virale B (2020) (0)
- Toxidermies au télaprévir, un inhibiteur de la protéase du VHC (2011) (0)
- COL07-05 - Bocéprévir associé à Peginterféron/Ribavirine dans le traitement de patients co-infectés par le VHC et le VIH : résultats de fin de traitement (Semaine 48) (2012) (0)
- CA27 - OBSERVATOIRE PONTS : VOLONTÉ DES SOIGNANTS ET DÉSIRS DES MALADES ASSURENT DES TRAITEMENTS EFFICACES DES HÉPATITES C CHEZ LES TOXICOMANES (2005) (0)
- Informations supplémentaires de l'article : Hépatites virales (2016) (0)
- Efficacité histologique de la ribavirine en monothérapie au cours du traitement de l'hépatite C chronique chez les malades transplantés rénaux (2008) (0)
- Prophylaxie des hépatites virales (1997) (0)
- [Editorial]. (2019) (0)
- Patients treated for hepatitis C: an observational study with the French administrative healthcare database (SNDS) (2020) (0)
- Retreatment of Sofosbuvir-Including Regimen Failures in the Real Life (2016) (0)
- [ANRS HC 02 RIBAVIC: from multicenter trial to daily practice]. (2009) (0)
- Hépatites virales C chez les hémodialysés et les transplantés rénaux (1994) (0)
- Dissociation of TNF and IL-1β production in chronic alcoholics without cirritosis (1991) (0)
- [Viral hepatitis: vaccinate and screen?] (2018) (0)
- La cinétique virale précoce n’est pas prédictive de la réponse au traitement par sofosbuvir + ribavirine (12 ou 24 semaines) chez les patients infectés par un génotype 2 ou 3 (étude VALENCE) (2014) (0)
- Génotypes du virus de l'hépatite B en France et formes sévères de la maladie hépatique : étude multicentrique (2008) (0)
- L’index FIB-4 pour faire le diagnostic de fibrose hépatique avancée au cours de la stéatose hépatique (2019) (0)
- Impact des nouveaux traitements (AAD) de l’hépatite C dans la population générale et les populations à risque : étude réalisée en France à partir des données du SNDS sur la période 2015-2019 (2021) (0)
- [Atheroma and hepatitis C virus]. (2002) (0)
- Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring? (2020) (0)
- Evaluation indépendante et analyse coût/efficacité des marqueurs biologiques non-invasifs de fibrose hépatique chez les patients co-infectés VIH-VHC : étude FIBROVIC-ANRS HC02 (2007) (0)
- HLA class II alleles and histological features in chronically infected HCV patients with persistently normal ALT levels (2001) (0)
- Traitement de l'hépatite chronique C chez les malades ayant une co-infection VIH : efficacité et tolérance (2002) (0)
- [Hepatotropic virus and renal transplantation]. (1996) (0)
- Virus de l’hépatite C : une élimination programmable (2019) (0)
- Hépatites virales, diagnostic, histoire naturelle et traitement (2013) (0)
- Relationship between Alcohol use Disorders and Response to Antiviral Treatment on the Prognosis of Cirrhotic Patients with Chronic Hepatitis C (2016) (0)
- La coinfection par les virus de l'hépatite C et de l'immunodéficience humaine (2000) (0)
- Treatment of hepatitis C : Perspectives Traitement des hépatites C : perspectives (2014) (0)
- CA19 - ÉVALUATION D'UN NOUVEAU MARQUEUR NON INVASIF DE FIBROSE (FIB-4) DANS UNE LARGE SÉRIE DE MALADES INFECTÉS PAR LE VHC (2005) (0)
- Autoévaluations de l'article : Foie et virus de l'immunodéficience humaine (2017) (0)
- Virus hépatotropes et transplantation rénale (1996) (0)
- COINFECTION VIH-VHC (2009) (0)
- Iconographies supplémentaires de l'article : Alcool, stéatohépatite métabolique, insulinorésistance et hépatite C (2008) (0)
- CA 21-Efficacité diagnostique du fib4 au cours de l’hépatite B chronique (2006) (0)
- Caractéristiques et réponse au traitement des malades infectés par un virus de l'hépatite C (VHC) de sérotype 4 en Ile de France (2008) (0)
- Comment traiter en cas de cirrhose virale B (2009) (0)
- Risques élevés de mitochondriopathie chez les sujets co-infectés VIH/VHC traités par l'association ddI/d4T et interféron (standard ou pégylé)/ribavirine (ANRS HC02-ribavic) (2008) (0)
- Autoévaluations de l'article : Hépatites virales (2016) (0)
- O.098 Changes in NK cell repertoire after therapeutic HBV vaccination could be correlated to induction of HBV-specific T-cell responses (2006) (0)
- Reply Prognosis of Covid-19 patients with chronic liver disease in France in 2020 (2021) (0)
- Nouveautés dans le traitement de l'hépatite C (2004) (0)
- 542 NEW ALGORITHM TO ASSESS FIBROSIS STAGE IN ALCOHOLIC LIVER DISEASE BY TRANSIENT ELASTOGRAPHY (2013) (0)
- Hépatite chronique C : résultats de la bithérapie (2002) (0)
- Hépatologie 98 - Paris - 12 décembre 1998 comment je traite l'hépatite chronique B par le vaccin anti-HBV (1999) (0)
- Réactivation du virus de l’hépatite B chez les patients traités par chimiothérapie pour une tumeur digestive (2017) (0)
- Efficacité et tolérance de la trithérapie antivirale (Peg-IFN alpha/ribavirine/inhibiteur de protéase) chez des patients présentant une vascularite cryoglobulinémique associée au VHC : résultats à 24 semaines (2012) (0)
- Iconographies supplémentaires de l'article : Foie et virus de l'immunodéficience humaine (2017) (0)
- GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE : BILAN DE LA SECTION HEPATOLOGIE, DE 1995 A 1997 (1998) (0)
- Comparing interferon‐free with interferon‐based regimens in HCV patients: Rogers phenomenon and Simpson’s paradox (2020) (0)
- Carcinome hépatocellulaire et hépatocarcinogenèse virale (2010) (0)
- Histoire naturelle de l’hépatite C chez les patients infectés par le VIH (2008) (0)
- Impact clinique de la caractérisation cytomorphologique et moléculaire (mutations du gène bêta caténine) des cellules tumorales qui circulent chez les patients atteints de carcinome hépatocellulaire (CHC) (2008) (0)
- CA10 - Induction d’une réponse cellulaire T spécifique anti-hbs chez des malades ayant une hépatite B chronique au cours d’un traitement par vaccination ADN (2004) (0)
- Prise en charge de l’infection par le virus de l’hépatite C chez les patients infectés par le VIH : évolution dans 3 cohortes consécutives entre 2004 et 2009 en France (2010) (0)
- [Treatment of chronic hepatitis B virus infection and hepatocellular carcinoma prevention]. (2015) (0)
- Impact de la résistance aux analogues antiviraux et stratégies thérapeutiques dans les situations rares (dialyse, transplantation rénale, vascularites et traitements pré-emptifs en situation d’immunosuppression) (2006) (0)
- 605 IDENTIFICATION OF T-CELL RESPONSES TO THE HEPATITIS B SPLICED PROTEIN (HBSP) OF HEPATITIS B VIRUS. ANRS STUDY: HB EP 02 (2010) (0)
- Efficacité virologique et histologique des traitements antiviraux de la cirrhose virale C (2008) (0)
- Prise en charge des hépatites virales : le parcours de soins en question (2006) (0)
- [Liver and ageing: clinical aspects]. (2003) (0)
- PORTEURS SAINS DE L'ANTIGENE HBS : IL PERSISTE DES RISQUES QUI JUSTIFIENT UNE SURVEILLANCE MINIMALE (1997) (0)
- Factors associated with liver fibrosis in HIV/HCV co-infected patients (2003) (0)
- ANRS HCO2 - Ribavic : un essai contrôlé randomisé comparant interféron ?-2B pégylé plus ribavirine vs interferon ?-2B plus ribavirine comme traitement initial de l'hépatite chronique C des co-infectés VIH-VHC (2008) (0)
- Is stronger better in curing hepatitis C virus infection? (2016) (0)
- What are the risks involved in kidney transplantation that is probably hepatitis B related. (1999) (0)
- 421 IS LIVER STIFFNESS ACCURATE TO DEFINE REGRESSION OF CIRRHOSIS IN PATIENTS CURED FROM CHRONIC HEPATITIS C (2009) (0)
- Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease (2020) (0)
- Benefits associated with HCV cure in people with mental disorders (2022) (0)
- P196 INVESTIGATION OF HEPATITIS C VIRUS ADAPTATION TO HOST GENETIC POLYMORPHISMS (2014) (0)
- [Nucleoside analogues resistance in the treatment of chronic hepatitis B virus infection]. (2003) (0)
- M1812 Baseline Characteristics and Week-4 Response Among 1546 CHC Patients Infected with HCV Genotype 1, 2, 3 and 4: Interim Results of the Prophesys Cohort (2009) (0)
- [ANRS HC 02 RIBAVIC: histo-pathological impact]. (2009) (0)
- P.235 Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus ribavirin assessed by HCV RNA measurement (2006) (0)
- PAGE-B and FIB-4 predict the occurence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study (2022) (0)
- 112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir) (2013) (0)
- Contrast-Enhanced Ultrasound in the Management of Cirrhotic Patients: HCC Diagnosis, Staging and Monitoring of Percutaneous Treatments (2006) (0)
- The role of direct antiviral agents for the treatment of chronic hepatitis C in special populations (2004) (0)
- A true revolution: enhanced motivation of the patient with rapid loss of virus (or rapid negativation of viral load), relationship between viral and histological cure. (2011) (0)
- Diversity of circulating HBV genomes and impact on viral infection (2022) (0)
- Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle (2022) (0)
- P.053 Spliced hepatitis B virus RNA and liver disease (2006) (0)
- [Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection: epidemiology, severity and recent therapeutic strategies]. (2005) (0)
- P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey (2015) (0)
- Daclatasvir: a promising triple therapy for children with chronic hepatitis C (2013) (0)
- [Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease]. (2007) (0)
- Practice point 46 – How to manage the hepatitis C virus co-infected HIV patient (2010) (0)
- 292 - Patient Reported Outcomes in Cirrhotic Patients with Chronic Hepatitis C: the Impact of Placebo, Active Treatment and Sustained Viral Eradication (2018) (0)
- Cost-Effectiveness and Budget Impact of Interferon-Free Direct-Acting Antiviral (DAA)-Based Regimens for Chronic Hepatitis C Treatment. The French Case (2016) (0)
- [Management of HCV-HIV patients]. (2007) (0)
- Treatment of hepatitis C (2011) (0)
- Évaluation de l’efficacité virologique et de la tolérance du traitement antiviral chez les patients porteurs d’une hépatite C chronique, associée à un lymphome B non hodgkinien : étude cas-témoins ANRS HC13 lympho-C (2014) (0)
- Exploration d'une cytolyse hépatique (2002) (0)
- The safe (sequential algorithm for fibrosis evaluation) biopsy: A new approach to stage fibrosis in chronic hepatitis C (2008) (0)
- Hepatitis viruses and kidney transplantation (1996) (0)
- P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER (2015) (0)
- 428 RAPID DECLINE OF LIVER STIFFNESS FOLLOWING ALCOHOL WITHDRAWAL IN HEAVY DRINKERS (2010) (0)
- Prevention of the mother‐to‐child transmission of Hepatitis B virus (2018) (0)
- Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells (2010) (0)
- [Treatment of hepatitis B. Current strategies]. (2007) (0)
- Traitement de l'Hépatite C Chronique chez les Patients Co- (2009) (0)
- OC.10.5: THE EFFECT OF PREVALENCE OF LIVER FIBROSIS STAGES IN PERFORMANCE OF NONINVASIVE FIBROSIS BIOMARKERS IN CHRONIC LIVER DISEASES (CLDS): RESULTS OF AN INDEPENDENT, INTERNATIONAL STUDY (2011) (0)
- Rapid diagnostic usefulness of liver biopsy in febrile cholestasis of AIDS (1991) (0)
- Prophylactic hepatitis B vaccination Present and future (1999) (0)
- Fatty liver index as a risk factor for all-cause and liver related mortality in patients under therapy for chronic hepatitis B (ANRS CO22 Hepather cohort study) (2022) (0)
- HLA class II alleles and histological features in chronically infected HCV patients with consistently normal ALT levels (2001) (0)
- 299 BASELINE CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF RIBAVIRIN >800 MG/DAY AMONG G2/3 PATIENTS PRESCRIBED PEGINTERFERON ALFA-2A (40KD) FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS FROM PROPHESYS (2010) (0)
- [Alcoholic hepatitis]. (2012) (0)
- Impact of antihiv tritherapy on HCV infection: biological and virological analysis (1998) (0)
- Su1424 Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis (2016) (0)
- [Management of chronic hepatitis in 2008]. (2008) (0)
- Reply to "Precision-cut human liver slice cultures as an immunological platform". (2020) (0)
- Viral hepatitis and the kidney. (2013) (0)
- [The therapeutic revolution of hepatitis C virus infection honored by a Nobel prize]. (2020) (0)
- Hepatocellular carcinoma (HCC) scoring system for the individualized prediction of liver cancer in 1080 HCV-related compensated cirrhosis included in the French multicenter prospective cohort ANRS CO12 CirVir (2015) (0)
- A controlled study of anti-HBV vaccine therapy in HBsAg healthy carriers (2001) (0)
- High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis (2017) (0)
- Reply to: “Association of chronic liver disease with the prognosis of COVID-19 patients” (2021) (0)
- 762 ADDITIONAL PEG-INTERFERON IN HBeAg-POSITIVE HIV CO-INFECTED PATIENTS ON cART INCLUDING TENOFOVIR: THE ANRS HB01 EMVIPEG STUDY (2013) (0)
- [The role of contrast-enhanced ultrasonography for the detection of hepatocellular carcinoma]. (2004) (0)
- Faut-il traiter le VHC des patients co-infectés VIH? Quand? Comment? (2004) (0)
- 429 Multicenter study of hepatitis B virus (HBV) genotypes in France: Geographic distribution, correlation with HBEAG-positive status and relation to liver fibrosis (2004) (0)
- The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort) (2016) (0)
- 821 RELATIONSHIP BETWEEN PLASMACYTOID AND MYELOID DENDRITIC CELLS AND RESPONSE TO ANTIVIRAL THERAPY (2008) (0)
- Iconographies supplémentaires de l'article : Traitements de l'infection par le virus de l'hépatite C (2017) (0)
- PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018 (2019) (0)
- P0675 : An ex vivo model of human liver slices culture for evaluating liver fibrogenesis (2015) (0)
- 1355 PRE-CLINICAL DATA SUPPORTS USE OF DPP4 INHIBITORS FOR THE PROTECTION OF AGONIST IP-10: A NOVEL MECHANISM TO ENHANCE ANTI-VIRAL LYMPHOCYTE CELL TRAFFICKING TO THE LIVER (2011) (0)
- Contrast-enhanced sonography of the liver: introducting a systematic approach for lesion detection and characterization (2002) (0)
- 536 Assessment of Paroxetine in the Prevention of Depression in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alpha Plus Ribavirin: A Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg (2010) (0)
- cells of infected patients by in situ hybridization Detection of hepatitis C virus RNA in peripheral blood mononuclear (2011) (0)
- SP0039 New Strategies for The Treatment of Hepatitis C (2016) (0)
- Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection (2016) (0)
- Pathological evolution of HCV-healthy carriers: A multivariate analysis (2003) (0)
- T-10 Effect of prevalence of fibrosis stages on the performance of non-invasive fibrosis biomarkers in chronic liver diseases (CLDs): Results of a large-scale, international study (2011) (0)
- Iconography : CO 7 - RÉPONSE ANTI-VIRALE DE L'ALBUMINE INTERFÉRON ALFA-2B EN ASSOCIATION A LA RIBAVIRINE CHEZ LES MALADES INFECTÉS PAR LE VHC DE GÉNOTYPE 1 NAÏFS DE TRAITEMENT ANTI-VHC (2006) (0)
- Mise au point - Histoire naturelle de l’infection par le virus de l’hépatite B (2008) (0)
- University of Southern Denmark Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography (2017) (0)
- 1429 BASELINE APOLIPOPROTEIN H (ApoH) IS A PREDICTOR OF EARLY VIROLOGIC RESPONSE TO TRIPLE THERAPY (ANRS CO20-CUPIC) (2013) (0)
- [662] IS CIRRHOSIS AT PRESENTATION A FACTOR OF POOR OUTCOME IN AUTOIMMUNE HEPATITIS? (2007) (0)
- 851 INHIBITION OF HEPATITIS C VIRUS INFECTIVITY BY ANTI-VIRAL DRUGS IN HUMAN HCV INFECTED LIVER SLICES CULTURE (2012) (0)
- [Hepatitis C facing the challenge of healing]. (2018) (0)
- Assessment of Baveno VI and expanded Baveno VI criteria for screening and follow-up of all-size esophageal varices in patients with compensated viral cirrhosis (ANRS/CO12 CirVir cohort) (2020) (0)
- 824 BASELINE AND IN-TREATMENT BIOMARKERS FOR RESPONSE TO INTERFERON-BASED THERAPY IN CHRONIC HEPATITIS C (2012) (0)
- 618 HCV-SPECIFIC IMMUNE RESPONSES IN UNINFECTED INDIVIDUALS WITH NO KNOWN RISK FOR HCV EXPOSITION (2008) (0)
- Autoévaluations de l'article : Traitements de l'infection par le virus de l'hépatite C (2017) (0)
- Reply to: "Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection". (2013) (0)
- Parallel derivation of isogenic human primed and naive induced pluripotent stem cells (2018) (0)
- 300 EVIDENCE FOR CXCL10 (IP-10) ANTAGONISM IN CHRONIC HCV INFECTION (2011) (0)
- P160: Study of human liver fibrogenesis using human liver slices culture as a model (2015) (0)
- [Epidemiology, transmission and screening of viral hepatitis]. (2013) (0)
- 12 REGRESSION OF HEPATITIS C-RELATED CIRRHOSIS AND LONG-TERM SURVIVAL (2008) (0)
- Treating patients with DAAs helped to save €1 billion in France - a budget impact model from 2014 to 2018 (2020) (0)
- Predictive models for hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis C and sustained virological response (SVR) achieved with direct acting anti-viral (DAA) included in the ANRS CO22 hepather cohort (2020) (0)
- 387 HEPATITIS DELTA IN FRANCE: RESULTS IN 188 PATIENTS ON THE FRENCH HEPATITIS DELTA NETWORK (2011) (0)
- [Viral hepatitis, diagnosis, natural history and treatment]. (2013) (0)
- 211 Effect of viral clearance on clinical outcome in patients with HCV-related cirrhosis or advanced fibrosis. A retrospective study in 138 patients (2004) (0)
- Diagnostic use of the Cobas HBV-PCR test in HBs Ag positive and HBV-DNA negative patients by standard hybridization (2002) (0)
- Non-Tumoral Portalvein Thrombosis and End-Stage Liver Disease in Patients with Cirrhosis: A Longitudinal Retrospective Cohort (2016) (0)
- Athérome et virus de l'hépatite C (2002) (0)
- 432 FIBROSIS STAGING PREDICTS VIROLOGICAL RESPONSE IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL (2011) (0)
- Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort) (2021) (0)
- C-SURFER : grazoprevir plus elbasvir chez des patients infectés par le VHC de génotype 1 et une insuffisance rénale chronique naïfs de traitement et pré-traités (2015) (0)
- FREE ORAL COMMUNICATIONS 2: ALCOHOL AND LIVER—CLINICAL RESEARCHO2.1RAPID DECLINE OF LIVER STIFFNESS WITH ALCOHOL WITHDRAWAL IN HEAVY DRINKERS (2011) (0)
- and Stanislas Pol withdrawal Hepatitis B virus treatment beyond the guidelines : special populations and consideration of treatment (2014) (0)
- T-28 Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study (2012) (0)
- Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth (2019) (0)
- [Clinical and Biological Gastroenterology: evaluation of Hepatology division, 1995 to 1997]. (1998) (0)
- A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals (2019) (0)
- A call to action toward integrated testing and earlier care for viral hepatitis, HIV, STIs and TB (2020) (0)
- Induction or expansion of T‐cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers (2004) (0)
- [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance]. (2002) (0)
- P.244 Pegylated interferon alpha-2a for treatment of acute hepatitis C in Egypt (ANRS 1213 trial) (2006) (0)
- Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort (2022) (0)
- Direct‐acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic? (2019) (0)
- [ANRS HC 02 RIBAVIC: from multicenter trial to daily practice. Conclusions]. (2009) (0)
- Quantification non-invasive du degré de Fibrose Hépatique par Élastographie Dynamique (Supersonic Shear Imaging) (2010) (0)
- [New recommendations for diagnosis and virological monitoring of viral hepatitis]. (2003) (0)
- Fixed-Dose Combination TherapyWith Daclatasvir , Asunaprevir , and Beclabuvir for Noncirrhotic Patients With HCVGenotype 1 Infection (2015) (0)
- NODULAR REGENERATIVE HYPERPLASIA IN HIV INFECTION: A PUZZLING CASE OF PORTAL HYPERTENSION IN A PATIENT COINFECTED WITH HUMAN IMMUNODEFICIENCY AND HEPATITIS C VIRUSES (2009) (0)
- 394 A promiscuous CD4+ T-cell epitope within HBx protein during chronic HBV infection (2006) (0)
- Sepsis and Meningitis Due to Capnocytophaga cynodegmi after Splenectomy (2005) (0)
- Regulation of cytosolic aspartate aminotransferase gene expression by glucocorticoids, insulin and cAMP (1990) (0)
- Early IFNβ secretion determines variable downstream IL-12p70 responses upon TLR4 activation (2022) (0)
- Infection par le virus de l'hépatite C et virus de l'immunodéficience humaine (1998) (0)
- [Hepatitis C in kidney recipients. Epidemiology and impact on kidney transplantation]. (1991) (0)
- Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France (2016) (0)
- Reply to: “Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database” (2021) (0)
- [Impact of resistance to analogue antivirals and therapeutic strategies in situations of dialysis, kidney transplantation, vasculitis, and preemptive treatments in immunosuppressed patients]. (2006) (0)
- P.057 Defective recognition of viral mutants by CD4+ T cells specific for a promiscuous HBx-derived epitope in HBV chronic carriers (2006) (0)
- Relation between HCV and HBV infections in alcoholics with or without HCC (1990) (0)
- [Economics and health policy: the example of hepatitis C viruses]. (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stanislas Pol?
Stanislas Pol is affiliated with the following schools:
